Over-the-Counter (OTC) Drugs and Dietary Supplements: Global Markets

 Published On: Mar, 2017 |    No of Pages: 150 |  Published By: BCC Research | Format: PDF
Request Free Sample
The global market for over the counter (OTC) drugs and dietary supplements reached $164.7 billion in 2016 and should reach $220.8 billion in 2021, with a compound annual growth rate (CAGR) of 6.0%.

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The study goal of this report is to understand the OTC drugs and dietary supplement market and provide five-year forecasts for the same.

The objective of the study is to inform stakeholders of the OTC drugs and dietary supplement industry about market dynamics of the industry that will help them in planning strategic initiatives.

REASONS FOR DOING THE STUDY
Over the counter (OTC) drugs and dietary supplements encourage people to engage in responsible self-care and to access safe and effective OTC drugs and dietary supplements at the nearest retail counters.

The market for OTC drugs and dietary supplements is still instable due to lack of clear policies on various issues such as contents on the package, sales authorization in stores other than pharmacies, policies on advertising and promoting OTC drugs at point of sales, policies for pharmacy only or behind the counter drugs, and many more. Issues regarding sales promotion and sales in outlets other than pharmacies raise higher concerns.

Regulatory issues are big hurdles in the growth of the OTC drugs market. The latest issue is that of refunds and reimbursing OTC drugs bills. People from various countries produce claims for OTC bills where irregularities were identified that were trying to move prescription drugs to OTC and did not help reduce the public health burden. Many nations are now making it compulsory to produce a prescription for compensating OTC drugs under medical billing. This has again brought sales of OTC drugs down since 2010.

There are no common policies and regulations worldwide and some countries follow US FDA guidelines and other follow the UK MHRA. Another key issue the industry faces is lack of a seamless reclassification of drugs from prescription to OTC. Drugs classified as OTC in one country are restricted in other country and need a prescription. This is another big issue in supply chain management and distribution of drugs especially for online pharmacies and multinational pharmacy chains.

BCC Research identified a need for the study of present markets for OTC drugs and dietary supplements on the basis of regulatory and supply chain issues and decided to find out what are the key initiatives and strategies worldwide to control these issues for market growth.

SCOPE OF REPORT
The report considers only western or modern drugs for this report and excludes any other type of drugs such as alternative therapies.

This study aims at understanding the dynamics and forecasts for OTC drugs and dietary supplements markets worldwide and provides key market propositions within the next five-year period.

The report covers developed and emerging markets in order to help readers understand:
-The current state of the OTC drugs and dietary supplements market and the key markets for its future development.
-New regulations that will influence the development of the OTC drugs and dietary supplements market.
-Market drivers of and threats to the OTC drugs and dietary supplements industry.
-Major regional trends in the global OTC drugs and dietary supplements market.
-The competitive thrust of the market.

INTENDED AUDIENCE
-Executives of pharmaceutical companies that are currently marketing OTC drugs and dietary supplements.
-Executives of companies that provide third-party manufacturing and development facilities for OTC drugs and dietary supplements.
-Manufacturers of bulk active ingredients and inactive ingredients such as base, resins, pigments and other raw materials for the manufacturing of OTC drugs and dietary supplements.
-FMCG companies that intend to enter the OTC drugs and dietary supplements market.
-Entrepreneurs, management consultants, and merger and acquisition (M&A) consultants.
-Financial institutions, venture capitalists and angel investors.
-Manufacturers and exporters of alternate OTC drugs and food supplements.
-Government agencies, public health departments and organizations working in regulations and process development of OTC drugs and dietary supplements.

INFORMATION SOURCES
The information and analysis presented in this BCC Research report are based on firsthand information from primary executives, product managers and clinical specialists; background information obtained from various government, business, medical journal and trade magazines; and statistical data from various governmental organizations and trade associations.

Key information from published literature was used to conduct interviews with industry participants in order to validate and obtain expert opinion on current and future trends. Interviews were also used to confirm and/or adjust market size and market share estimates as well as to formulate market projections Data are expressed in 2015 U.S. dollars. The base year is 2015. Historical data are provided for 2014 and forecast data are provided for 2016 and 2021. Historical, base year and forecast data are provided for each market segment and sub-segment.
Chapter- 1: INTRODUCTION  4      
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE OF REPORT
INTENDED AUDIENCE
INFORMATION SOURCES
ANALYST'S CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER

Chapter- 2: SUMMARY 5 $250
GLOBAL OTC DRUG MARKETS BY LEADING THERAPEUTIC SEGMENTS, 2016 THROUGH 2021
GLOBAL DIETARY SUPPLEMENT MARKETS, 2016 THROUGH 2021

Chapter- 3: OVERVIEW 13 $865
EVOLUTION OF OTC DRUGS
KEY GROWTH FACTORS FOR OTC DRUGS AND DIETARY SUPPLEMENT MARKETS
INDUSTRY DRIVERS FOR OTC DRUGS
RULES AND REGULATIONS FOR OTC DRUGS AND DIETARY SUPPLEMENTS
MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENTS

Chapter- 4: GLOBAL OTC DRUGS AND DIETARY SUPPLEMENT MARKETS     6 $399
GLOBAL MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENTS 2016 THROUGH 2021
REGIONAL MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENT MARKETS 2016 THROUGH 2021
GLOBAL SALES FORECAST FOR OTC DRUGS BY THERUPEUTIC CLASSIFICATION
GLOBAL OTC DRUGS AND DIETARY SUPPLEMENT MARKETS BY LOCATION OF SALES 2016 THROUGH 2021

Chapter- 5: OTC DRUGS AND DIETARY SUPPLEMENT MARKETS IN THE AMERICAS     13 $865
OTC DRUGS AND DIETARY SUPPLEMENT MARKETS IN NORTH AMERICA 2016 THROUGH 2021
OTC DRUGS AND DIETARY SUPPLEMENTS IN THE U.S.
VENDOR ECOSYSTEM FOR OTC DRUGS IN THE U.S.

Chapter- 6: THE OTC DRUG AND DIETARY SUPPLEMENT MARKETS IN EUROPE 22     $1463
BREXIT EFFECT ON THE OTC DRUG MARKET IN EUROPE
OTC DRUGS AND DIETARY SUPPLEMENT MARKETS IN EUROPE 2016 - 2021
OTC DRUGS AND DIETARY SUPPLEMENT MARKETS: WESTERN EUROPE THROUGH 2021
THE U.K. OTC DRUG MARKET
GERMAN OTC DRUG AND DIETARY SUPPLEMENTS MARKET
FRANCE'S OTC DRUGS MARKET 2016 THROUGH 2021
OTC DRUGS AND DIETARY SUPPLEMENT MARKETS IN CENTRAL AND EASTERN EUROPE

Chapter- 7: OTC DRUGS AND DIETARY SUPPLEMENT MARKETS IN ASIA-PACIFIC 16     $1064
 APAC OTC DRUGS MARKETS 2016 THROUGH 2021

Chapter- 8: GLOBAL MARKET FORECAST FOR OTC DRUGS BY THERUPEUTIC CLASSIFICATION 20 $1330
OTC ANALGESICS/ANTIPYRETICS MARKETS 2021
OTC ANTIHISTAMINE AND COUGH AND COLD DRUGS MARKETS 2021
OTC GASTROINTESTINAL PRODUCTS MARKETS 2021
OTC DERMATOLOGICAL DRUGS MARKETS 2021
OTC ORAL MEDICAL CARE PRODUCTS MARKETS 2021
GLOBAL MARKET FORECAST FOR OTC EYE CARE PRODUCTS
OTC SMOKING CESSATION PRODUCTS MARKETS 2021
OTC DIETARY SUPPLEMENTS (VMS) MARKETS 2021
GLOBAL MARKET FORECAST THROUGH 2021

Chapter- 9: OTC DRUG INDUSTRY ROADMAP     6 $399
THE PRACTICE OF BUYING OTC DRUGS
ROLE OF PHARMACY IN OTC DRUGS
REGULATORY INFLUENCE ON OTC DRUG MARKET
KEY STRATEGIC INITIATIVES FOR MARKET PENETRATION AND EXPANSION
DRIVERS OF AND BARRIERS TO THE OTC DRUG INDUSTRY
STRENGTHS, WEAKNESSES, OPPORTUNITIES AND THREATS (SWOT) ANALYSIS OF THE OTC DRUG AND DIETARY SUPPLEMENT INDUSTRY

Chapter- 10: COMPANY PROFILES     21 $1397
 ALACER CORP.
ALCON INC.
ALFRESA PHARMA CORPORATION
ALKALON A/S
ALLIANCE HEALTHCARE
ALLERGAN, PLC.
ALTICOR
ARKOPHARMA PHARMACEUTICAL LABORATORIES (LABORATOIRES PHARMACEUTIQUES)
ASPEN HOLDINGS
BAUSCH & LOMB
BAYER HEALTHCARE AG
BOEHRINGER INGELHEIM GMBH
CARMA LABORATORIES, INC.
CHATTEM INC.
CILAG AG
COLGATE-PALMOLIVE COMPANY
DAIICHI SANKYO CO., LTD.
DERMA SCIENCES
EYESCIENCE LABS
FERTIN PHARMA A/S
GABA GMBH, PC
GALDERMA S.A.
GEMINI PHARMACEUTICALS, INC.
GENOMMA LAB INTERNATIONAL
GLAXOSMITHKLINE PLC
HISAMITSU PHARMACEUTICAL CO., INC.
JOHNSON & JOHNSON
KOWA COMPANY, LTD.
LAKE CONSUMER PRODUCTS, INC.
MANX HEALTHCARE LIMITED
MCM KLOSTERFRAU VERTRIEBS GMBH (KLOSTERFRAU HEALTHCARE GROUP)
MEDA AB
MELALEUCA, INC.
MERCK CORPORATE HEADQUARTERS
MERZ PHARMA
MOCHIDA PHARMACEUTICAL CO., LTD.
NEPENTES SA/NEPENTES PHARMA SP. Z O.O.
NEUTROGENA CORP.
NORTHEAST PHARMACEUTICAL GROUP CO. LTD
NOVARTIS INTERNATIONAL AG
NOW FOODS
PERRIGO PLC
PFIZER INC.
PGT HEALTHCARE (DIVISION OF PROCTER & GAMBLE)
PHARMAVITE LLC
PIERRE FABRE PHARMACEUTICALS INC.
PIRAMAL HEALTHCARE LTD
PRESTIGE BRANDS HOLDINGS, INC.
RECKITT BENCKISER PLC.
RECORDATI PHARMA GMBH
REVOLYMER (U.K.) LTD
SAGE PRODUCTS LLC
SANOFI
SATO PHARMACEUTICAL CO., LTD.
SHAKLEE CORPORATION
STADA ARZNEIMITTEL AG
SWISSE WELLNESS PTY LTD.
TAISHO PHARMACEUTICAL HOLDINGS
TAKEDA PHARMACEUTICALS LTD.
TISSO NATURPRODUKTE GMBH
WELLSPRING PHARMACEUTICAL CORPORATION
ZEAVISION, LLC

Chapter- 11: APPENDIX I 5 $333
MARKET DEFINITIONS
COMMON ADMINISTRATION METHODS FOR OTC DRUGS

Chapter- 12: APPENDIX II 14     $931
SMOKING CESSATION INITIATIVES

Chapter- 13: APPENDIX III     5 $333
 OTC MARKETS 2013 THROUGH 2018
HIGHLIGHTS OF THE YEAR 2012
TRENDS IN OTC DRUGS AND DIETARY SUPPLEMENTS THROUGH 2018
FORECAST TRENDS IN OTC DRUGS BY THERAPEUTIC CLASS THROUGH 2018

List of Tables

Summary Table A : GLOBAL THERAPEUTIC MARKETS FOR OTC DRUGS, BY SEGMENT, THROUGH 2021
Summary Table B : REGIONAL MARKETS FOR DIETARY SUPPLEMENTS, THROUGH 2021
Table 1 : GLOBAL MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENTS, THROUGH 2021
Table 2 : REGIONAL MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENTS THROUGH 2021
Table 3 : GLOBAL MARKET FOR OTC DRUGS, BY THERUPEUTIC CLASSIFICATION, THROUGH 2021
Table 4 : OTC DRUGS REVENUE BY LOCATION OF SALES, THROUGH 2021
Table 5 : DIETARY SUPPLEMENTS REVENUE BY LOCATION OF SALES, THROUGH 2021
Table 6 : NORTH AMERICA OTC DRUG MARKETS, THROUGH 2021
Table 7 : NORTH AMERICA DIETARY SUPPLEMENT MARKETS, THROUGH 2021
Table 8 : NORTH AMERICA MARKETS BY THERAPEUTIC CLASSIFICATION, THROUGH 2021
Table 9 : UPDATED LIST OF RX-TO-OTC SWITCHES IN THE U.S. FROM 2001 TO 2016
Table 10 : THE U.S. OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFCATIONS, THROUGH 2021
Table 11 : BRAZIL OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021
Table 12 : EUROPEAN OTC DRUG MARKETS, THROUGH 2021
Table 13 : EUROPEAN OTC DRUG MARKETS BY THERAPEUTIC CLASSIFCATIONS, THROUGH 2021
Table 14 : U.K. POM TO P RECLASSIFICATIONS UP TO OCTOBER 2016
Table 15 : P TO GSL RECLASSIFICATIONS UP TO OCTOBER 2016
Table 16 : RECENT POM TO P RECLASSIFICATIONS AND NONPRESCRIPTION MARKETING AUTHORIZATIONS: U.K., 2010-2015
Table 17 : RECENT P TO GSL RECLASSIFICATIONS AND NONPRESCRIPTION MARKETING AUTHORIZATIONS - U.K., 2011-2015
Table 18 : THE U.K. OTC DRUG MARKET, BY THERAPEUTIC CLASSIFICATION, THROUGH 2021
Table 19 : OTC DRUG SWITCHES IN GERMANY FROM 2005 TO 2016
Table 20 : GERMANY OTC DRUG MARKETS BY THERAPEUTIC CLASSIFCATIONS, THROUGH 2021
Table 21 : FRANCE OTC DRUG MARKETS BY THERAPEUTIC CLASSIFCATIONS, THROUGH 2021
Table 22 : CCE OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFCATIONS, THROUGH 2021
Table 23 : RUSSIAN OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021
Table 24 : POLISH OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021
Table 25 : APAC OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021
Table 26 : REVIEWS CONDUCTED FOR OTC DRUGS IN JAPAN, BY FISCAL YEAR, 2011-2015
Table 27 : UPDATED LIST OF OTC TO FIRST KIND PHARMACEUTICAL DRUGS IN JAPAN, NOV. 2007-MARCH 2016
Table 28 : JAPAN OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021
Table 29 : CHINA OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021
Table 30 : INDIA OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021
Table 31 : AUSTRALIA AND NEW ZEALAND OTC DRUG MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021
Table 32 : GLOBAL MARKET FORECAST FOR OTC ANALGESICS AND ANTIPYRETICS, THROUGH 2021
Table 33 : GLOBAL MARKET FORECAST FOR OTC ANTIHISTAMINE AND COUGH AND COLD, THROUGH 2021
Table 34 : GLOBAL MARKET FORECAST FOR OTC GASTROINTESTINAL PRODUCTS, THROUGH 2021
Table 35 : GLOBAL MARKET FORECAST FOR OTC DERMATOLOGICAL DRUGS, THROUGH 2021
Table 36 : GLOBAL MARKET FORECAST FOR OTC ORAL MEDICAL CARE PRODUCTS THROUGH 2021
Table 37 : GLOBAL MARKET FORECAST FOR OTC EYE CARE PRODUCTS, THROUGH 2021
Table 38 : GLOBAL MARKET FORECAST FOR OTC SMOKING CESSATION PRODUCTS, BY REGION, THROUGH 2021
Table 39 : GLOBAL MARKET FORECAST FOR OTC DIETARY SUPPLEMENT PRODUCTS, BY REGION, THROUGH 2021
Table 40 : SWOT ANALYSIS OF THE OTC DRUG AND DIETARY SUPPLEMENT INDUSTRY
Table 41 : ARTICLES REPORTED TO HAVE HIGHEST IMPLEMENTATION RATES IN 2012 WHO FCTC PROGRESS REPORT
Table 42 : ARTICLES REPORTED MODERATE IMPLEMENTATION RATES: 2012 WHO FCTC PROGRESS REPORT
Table 43 : ARTICLES REPORTED LOWEST IMPLEMENTATION RATES: 2012 WHO FCTC PROGRESS REPORT
Table 44 : GLOBAL IMPLEMETATION OF FCTC ARTICLES: 2012 REPORT
Table 45 : GLOBAL IMPLEMENTATION OF ARTICLE 14 OF FCTC
Table 46 : INITIATIVES IMPLEMENTED BY PARTIES TO FCTC TREATY IN 2012
Table 47 : PROJECTED GLOBAL CAUSE OF DEATH BY DISEASE
Table 48 : PUBLIC HEALTH BURDEN DUE TO SMOKING-RELATED DISEASES
Table 49 : GLOBAL MARKET FOR OTC DRUGS AND DIETARY SUPPLEMENTS THROUGH 2018

List of Figures

Summary Figure A : GLOBAL THERAPEUTIC MARKETS FOR OTC DRUGS, BY SEGMENT, 2015-2021
Summary Figure B : REGIONAL MARKETS FOR DIETARY SUPPLEMENTS, 2015-2021
Figure 1 : KEY GROWTH FACTORS FOR OTC DRUGS
Figure 2 : GLOBAL IMPLEMENTATION OF ARTICLES OF 2012 WHO FCTC PROGRESS REPORT
Figure 3 : ONGOING STUDIES, BY REGION
Figure 4 : GLOBAL MARKET FOR OTC DRUGS AND DIETARY SUPPLEMENTS, 2011-2018

If the above report does not have the information suitable for your business, we can provide custom research that can be lucrative for your business or enhance your profession.